Opioid Crisis: Federal Response and Substance Abuse Policy

The modern opioid crisis originated in the late 1990s when pharmaceutical companies aggressively marketed prescription opioids such as OxyContin, downplaying addiction risks and encouraging broader prescribing for chronic pain. Prescription opioid sales quadrupled between 1999 and 2010, accompanied by a parallel increase in opioid-related overdose deaths. As prescribing restrictions tightened, many individuals with opioid dependence transitioned to heroin, followed by the introduction of illicitly manufactured fentanyl into the drug supply, which accelerated overdose deaths due to fentanyl's extreme potency (50-100 times more potent than morphine).

Federal response efforts have included the Comprehensive Addiction and Recovery Act of 2016 (CARA), which authorized expanded access to naloxone and MAT, and the SUPPORT for Patients and Communities Act of 2018, which addressed a broad range of issues including Medicaid coverage for substance use treatment, prescribing guidelines, drug scheduling, and reauthorization of the Office of National Drug Control Policy. State and local governments have also pursued litigation against pharmaceutical manufacturers and distributors, resulting in settlements exceeding $50 billion.

The Controlled Substances Act provides the framework for scheduling opioids and regulating their manufacture, distribution, and dispensing. The DEA administers registration of manufacturers, distributors, and prescribers, and enforces against diversion and illegal trafficking. The Ryan Haight Online Pharmacy Consumer Protection Act requires in-person medical evaluations before controlled substances can be prescribed online, though COVID-era flexibilities for buprenorphine telehealth prescribing have been extended.

SAMHSA administers the State Opioid Response (SOR) grants, which provide approximately $1.5 billion annually to states for prevention, treatment, and recovery support services. The Certified Community Behavioral Health Clinic (CCBHC) model provides comprehensive mental health and substance use services with enhanced Medicaid reimbursement. The elimination of the X-waiver requirement for buprenorphine prescribing in the Consolidated Appropriations Act of 2023 removed a significant barrier to treatment access by allowing any DEA-registered prescriber to prescribe buprenorphine for opioid use disorder.

Treatment expansion options include increasing SAMHSA grant funding, expanding Medicaid coverage and reimbursement for substance use disorder services, reforming the methadone delivery system to allow pharmacy-based dispensing, increasing the behavioral health workforce, and integrating substance use treatment into primary care and emergency department settings. Harm reduction proposals include expanding access to naloxone (the opioid overdose reversal medication), supporting syringe services programs, drug checking services, and considering safe consumption sites.

Supply-side approaches include enhancing DEA enforcement against fentanyl trafficking, targeting precursor chemical supply chains (primarily from China), increasing international cooperation on drug interdiction, scheduling fentanyl analogs permanently, and strengthening postal inspection of international mail and parcels. The balance between enforcement and public health approaches remains a central policy tension, with advocates for harm reduction arguing that criminalization-focused strategies have proven ineffective and that reducing overdose deaths should be the paramount objective.

Overdose death trends have shown modest improvement, with preliminary data for late 2023 and 2024 indicating a potential plateau or decline in some regions, attributed in part to expanded naloxone distribution, increased treatment access, and shifting drug supply patterns. Xylazine, a veterinary sedative increasingly found mixed with fentanyl, has emerged as a complicating factor, as xylazine-related complications (including severe skin wounds) do not respond to naloxone. Congressional activity has included efforts to permanently schedule fentanyl-related substances, increase funding for treatment and harm reduction, and address the xylazine threat. The outcomes of pharmaceutical litigation continue to fund state and local responses to the crisis.